Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB +10.00% 3-Year EBITDA Growth Rate is 64.30% as of Jun. 2026. The stock has 8 warning signs investors should review. Among 688 Medical Devices & Instruments companies, CurveBeam AI ranks better than 92.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 64.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of CurveBeam AI was 64.30% per year. The lowest was -51.80% per year. And the median was -9.00% per year.
CurveBeam AI (ASX:CVB) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CurveBeam AI 3-Year EBITDA Growth Rate Related Terms
ASX:CVB vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, CurveBeam AI's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's 3-Year EBITDA Growth Rate falls into.
CurveBeam AI 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 64.30% mean?
CurveBeam AI (ASX:CVB) has a 3-Year EBITDA Growth Rate of 64.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #49 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 7.1%.
Is CurveBeam AI's 3-Year EBITDA Growth Rate too high?
CurveBeam AI's current 3-Year EBITDA Growth Rate is 64.30%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. CurveBeam AI's value of 64.30% is 693.8% above this industry median. Based on the distribution chart, CurveBeam AI ranks #49 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does CurveBeam AI's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #49 out of 688 companies for 3-Year EBITDA Growth Rate. This places CurveBeam AI in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. CurveBeam AI's value of 64.30% is 693.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current 3-Year EBITDA Growth Rate of 64.30% is 693.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current 3-Year EBITDA Growth Rate is 64.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
Based on GuruFocus' analysis, CurveBeam AI (ASX:CVB) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.06, compared to a current price of A$0.02 — trading 63.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 64.30% and 693.8% above the Medical Devices & Instruments industry median of 8.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current 3-Year EBITDA Growth Rate is 64.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
